The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...
Prostate involvement was first reported in IgG4-RD approximately 2 decades ago and comprises only 9.6% of cases. A male patient in his 7os presented with isolated prostatitis associated with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results